Minsheng Royal CSI Biotechnology Theme ETF

Morgan Stanley Predicts China's Biotech Sector to Fluctuate in H1 and See Clearer Direction in H2

Shenzhen Releases Action Plan for Insurance Industry to Support Innovation

588130

159892

513700

159859

512010

512290

159837

516930

159316

159615

159102

159992

159849

588250

Antengene has appointed Bing Hou as chief scientific officer, effective May 19, 2026. He will oversee drug discovery and R&D efforts, reporting to CEO Jay Mei. Hou, who joined Antengene in 2019, previously served as vice president of discovery science. He holds a PhD in biomedicine and has over 40 patent applications.

PUBT

ChinaAMC SSE STAR Biology and Medicine ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

iShares Global Healthcare

GF CSI HK Innovative Drugs Industry ETF(QDII)

ChinaAMC SSE Health Care ETF Initiating Fund

Penghua CSI HK Connect Health Care Composite ETF

Tianhong CNI BIOMEDICINE ETF

SPDR S&P Biotech

Direxion S&P Biotech Bull 3X

E Fund CSI 300 Health Care ETF

First Trust NYSE Arca Biotech Index Fd

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Health Care Select Sector SPDR

Guotai CSI Bio-medicine ETF

Invesco Nasdaq Biotechnology ETF

E Fund CSI Biotechnology Theme ETF

E Fund Hang Seng SCHK Innovative Drug ETF

China Southern Hang Seng Biotech ETF(QDII)

Invesco Biotechnology & Genome ETF

ALPS Medical Breakthrough

Bosera Hang Seng SCHK Innovative Drug Select ETF

iShares Biotechnology ETF

Huaan Hang Seng Biotech ETF

BlackRock, Inc.

VanEck Biotech ETF

VG Health

iShares US Pharma

Yinhua CSI Innovative Drugs Industry ETF

China Merchants CSI Biotechnology Theme ETF

Penghua SSE STAR Biology and Medicine ETF

Bosera Hang Seng Health Care ETF(QDII)

ANTENGENE-B

Antengene appoints Bing Hou as chief scientific officer

01011

516500

China NT Pharma Group Co., Ltd. disclosed details regarding the resignation of independent non-executive director Mr. Ng Ming Kwan, who cited governance issues and lack of involvement in key transactions as reasons for his departure. He raised concerns about the accuracy of disclosures and internal compliance processes. The board noted that Mr. Ng's statement reflects his views and is reviewing the issues he raised, indicating potential ongoing scrutiny of governance and compliance practices.

Tip Ranks

NT PHARMA

Guotai SSE STAR Brand Name Drug ETF

China Universal 800 Health Care ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

ChinaAMC CSI Biotechnology Theme ETF

China NT Pharma Discloses Governance Dispute Behind Director’s Resignation

The Purina Institute is advancing microbiome science in veterinary medicine, focusing on the gut-brain axis and antimicrobial stewardship. Their Microbiome Forum highlighted how gut health influences neurological conditions in pets and emphasized the need for responsible antimicrobial use to protect long-term health. By translating complex research into practical insights, the Institute aims to empower veterinarians to enhance pet health through informed dietary and treatment strategies.

prnewswire

Proshares Ultra Nasdaq Biotech

Proshares UltraShort Nasdaq Biotech

08:59 ETPurina Institute Drives the Conversation on Microbiome Innovation in Veterinary Medicine

513290

Annovis Bio, Inc. announced a proposed underwritten public offering of common stock and accompanying warrants. The offering aims to raise funds for the clinical development of its lead compound, buntanetap, for Alzheimer's and Parkinson's diseases. Canaccord Genuity is the sole bookrunner. The offering is subject to market conditions and is detailed in a preliminary prospectus to be filed with the SEC.

StockTitan

China Universal NASDAQ Biotechnology Technology ETF(QDII)

Annovis Bio

Annovis Announces Launch of Proposed Public Offering of Common Stock and Accompanying Warrants | ANVS Stock News

Nanjing's Leads Biolabs Co., Ltd. revealed today that their exclusive PD-L1/4-1BB bispecific antibody, Opamtistomig (LBL-024), has been approved by the Center for Drug Evaluation. This announcement was made under the Stock Code.

Unusual Whales

LEADS BIOLABS-B

Leads Biolabs' PD-L1/4-1BB Bispecific Antibody Wins Pivotal Phase III Approval, Set to Reshape the Frontline Treatment Landscape for Advanced EP-NEC

Nanjing Leads Biolabs Co., Ltd. announced that its PD-L1/4-1BB bispecific antibody, Opamtistomig, has received approval for a pivotal Phase III trial for advanced extrapulmonary neuroendocrine carcinoma (EP-NEC). This marks a shift from late-line to first-line treatment, expanding its patient population. The study, led by Professor Lin Shen, aims to validate Opamtistomig's potential to improve patient survival. The company plans to submit a Biologics License Application in Q3 2026 and is advancing multiple trials across various solid tumor indications.

21:35 ETLeads Biolabs' PD-L1/4-1BB Bispecific Antibody Wins Pivotal Phase III Approval, Set to Reshape the Frontline Treatment Landscape for Advanced EP-NEC

01801

159570

Innovent Biologics showcased its next-generation bispecific antibodies at the 2026 ATS and ARVO Conferences. Key presentations included IBI3002, targeting IL-4Rα/TSLP for asthma, IBI3038 for lung fibrosis, and IBI3031 for Thyroid Eye Disease. These candidates demonstrated promising preclinical and clinical results, indicating potential for improved therapeutic efficacy in autoimmune and ophthalmological diseases.

INNOVENT BIO

China Universal CNI HK Connect Innovative Drugs Industry ETF

Guotai CSI Hugangshen Innovative Drugs Industry ETF

20:00 ETInnovent Showcased Clinical and Preclinical Results of Next-Generation Autoimmune and Ophthalmology Pipeline at the 2026 ATS and ARVO Conferences

TransThera Sciences (Nanjing), Inc. is raising HK$156 million through a placement of 3,836,000 new H shares at HK$40.83 each, an 18% discount to market prices. This represents 1.24% of its existing H-share capital and aims to broaden the shareholder base despite modest dilution for current holders. The transaction is subject to regulatory approvals and may not complete, posing execution risks as the company seeks capital for operations and strategic plans.

Fullgoal CSI Hugangshen Innovative Drugs Industry ETF

Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII)

TRANSTHERA-B

TransThera Sciences to Raise HK$156 Million via Discounted H-Share Placement

Phase 2 trial results have revealed that efdoralprin alfa showed superior performance compared to standard-of-care augmentation therapy in increasing fAAT levels in patients with AATD. The data highlights the efficacy of efdoralprin alfa in achieving higher levels of fAAT.

Ark Genomic Revolution ETF

Press Release: ATS: phase 2 data demonstrate the superiority of efdoralprin alfa over a standard-of-care augmentation therapy in achieving higher fAAT levels in AATD

09995

688331

RemeGen Co. Ltd. plans to amend its articles of association to increase registered capital and total issued A shares due to its 2022 and 2023 Restricted A Share Incentive Schemes. The company will also update internal governance documents to enhance compliance and internal controls, with changes to be approved at the 2025 annual general meeting. This move aims to align governance with regulatory guidelines and improve oversight of board operations and executive pay.

REMEGEN

RemeGen

RemeGen Plans Governance and Articles Overhaul Following Share Incentive Issuances

Minsheng Royal CSI Biotechnology Theme ETF(516930.SH)